Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved

被引:18
作者
Abass, Khaled [1 ]
Reponen, Petri [1 ,2 ]
Mattila, Sampo [2 ]
Pelkonen, Olavi [1 ]
机构
[1] Univ Oulu, Inst Biomed, Pharmacol & Toxicol Unit, FI-90014 Oulu, Finland
[2] Univ Oulu, Dept Chem, FI-90014 Oulu, Finland
基金
芬兰科学院;
关键词
Pesticides; Xenobiotic; Risk assessment; In vitro metabolism; P450; LC-MS; HUMAN LIVER-MICROSOMES; RISK-ASSESSMENT; RAT CYTOCHROME-P450; ENZYMES; CHLORPYRIFOS; CARBOFURAN; INHIBITION; MOUSE; INDUCTION; CDNA;
D O I
10.1016/j.cbi.2010.03.024
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
This study aims to characterize interindividual variability and individual CYP enzymes involved in the in vitro metabolism of the carbamate insecticide carbosulfan. Microsomes from ten human livers (HLM) were used to characterize the interindividual variability in carbosulfan activation. Altogether eight phase I metabolites were analyzed by LC-MS. The primary metabolic pathways were detoxification by the initial oxidation of sulfur to carbosulfan sulfinamide ('sulfur oxidation pathway') and activation via cleavage of the nitrogen sulfur bond (N-S) to give carbofuran and dibutylamine ('carbofuran pathway'). Differences between maximum and minimum carbosulfan activation values with HLM indicated nearly 5.9-, 7.0, and 6.6-fold variability in the k(m), V(max) and CL(int) values, respectively. CYP3A5 and CYP2B6 had the greatest efficiency to form carbosulfan sulfinamide, while CYP3A4 and CYP3A5 were the most efficient in the generation of the carbofuran metabolic pathway. Based on average abundances of CYP enzymes in human liver, CYP3A4 contributed to 98% of carbosulfan activation, while CYP3A4 and CYP2B6 contributed 57 and 37% to detoxification, respectively. Significant correlations between carbosulfan activation and CYP marker activities were seen with CYP3A4 (omeprazole sulfoxidation), CYP2C19 (omeprazole 5-hydroxylation) and CYP3A4 (midazolam 1'-hydroxylation), displaying r(2) = 0.96, 0.87 and 0.82, respectively. Activation and detoxification pathways were inhibited by ketoconazole, a specific CYP3A4 inhibitor, by 90-97% and 47-94%, respectively. Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM. These results suggest that the carbosulfan activation pathway is more important than the detoxification pathway, and that carbosulfan activation is predominantly catalyzed in humans by CYP3A4. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:163 / 173
页数:11
相关论文
共 58 条
[1]
Characterization of Diuron N-demethylation by mammalian hepatic Microsomes and cDNA-Expressed human cytochrome p450 enzymes [J].
Abass, Khaled ;
Reponen, Petri ;
Turpeinen, Miia ;
Jalonen, Jorma ;
Pelkonen, Olavi .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (09) :1634-1641
[2]
In vitro metabolism and interaction of profenofos by human, mouse and rat liver preparations [J].
Abass, Khaled ;
Reponen, Petri ;
Jalonen, Jorma ;
Pelkonen, Olavi .
PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY, 2007, 87 (03) :238-247
[3]
Metabolism of carbosulfan. I. Species differences in the in vitro biotransformation by mammalian hepatic microsomes including human [J].
Abass, Khaled ;
Reponen, Petri ;
Mattila, Sampo ;
Pelkonen, Olavi .
CHEMICO-BIOLOGICAL INTERACTIONS, 2009, 181 (02) :210-219
[4]
Äbelö A, 2000, DRUG METAB DISPOS, V28, P966
[5]
[Anonymous], 2000, PESTICIDE MANUAL
[6]
AOYAMA T, 1989, J BIOL CHEM, V264, P10388
[7]
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[8]
Malathion bioactivation in the human liver: The contribution of different cytochrome P450 isoforms [J].
Buratti, FM ;
D'Aniello, A ;
Volpe, MT ;
Meneguz, A ;
Testai, E .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (03) :295-302
[9]
Evidences for CYP3A4 autoactivation in the desulfuration of dimethoate by the human liver [J].
Buratti, Franca A. ;
Testai, Emanuela .
TOXICOLOGY, 2007, 241 (1-2) :33-46
[10]
BURKE MD, 1977, DRUG METAB DISPOS, V5, P1